B. Riley Upgrades Eton Pharmaceuticals (NASDAQ:ETON) to “Strong-Buy”

by · The Markets Daily

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) was upgraded by investment analysts at B. Riley to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Several other brokerages also recently commented on ETON. HC Wainwright increased their price target on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, January 6th. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday.

Check Out Our Latest Analysis on Eton Pharmaceuticals

Eton Pharmaceuticals Trading Up 11.9 %

NASDAQ ETON opened at $13.44 on Thursday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The firm’s fifty day simple moving average is $11.64 and its 200-day simple moving average is $7.35. The company has a market capitalization of $350.13 million, a PE ratio of -61.09 and a beta of 1.38.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at $54,000. Jane Street Group LLC acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $90,000. Renaissance Technologies LLC increased its position in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares in the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Further Reading